Acadia Pharmaceuticals Inc. (ACAD)

[gi197845]

Yes, when Axon is FDA approved soon (since it has been granted an FDA, fast track designation) for the treatment of visual hallucinations disorder in dementia with Lewy bodies (DLB)...the ACAD share price will drop in half, like a rock. It's too bad that ACAD doesn't have fast track approval. Expect ACAD to be at $15 per sharem maximum after Axon approval. Then, expect ACAD to be at $7 per share after the additional Nuplazid indication fails to meet end points.